Skip to main content Skip to navigation

2020-21 Warwick Evidence Projects

top banner image hip

2020-21 Warwick Evidence Projects


This year we have been and are working on the following projects:

  • Venetoclax with obinutuzumab for untreated chroniclymphocytic leukaemia ID1402
  • Brolucizumab for wet age‐related macular degeneration ID1254
  • Encorafenib in combination with cetuximab and/or binimetinib for BRAF‐mutant metastatic colorectal cancer [ID1598]
  • Olaparib for previously treated, hormone‐relapsed metastatic prostate cancer (ID1640)
  • Ofatumumab for treating relapsing multiple sclerosis (ID1677)
  • Lisocabtagene maraleucel for treating large B‐cell lymphoma after at least 2 therapies (part 1) ID1444
  • Inclisiran for primary, high cardiovascular risk hypercholesterolemia (ID1647) 03‐Nov‐20 19‐Jan‐21 11‐May‐21 0.800 0.200
  • Lisocabtagene maraleucel for treating large B‐cell lymphoma after at least 2 therapies (part 2) (ID1444)
  • Update of DG21 Integrated sensor‐augmented pump therapy systems for managing blood glucose levels in type 1 diabetes
  • Ixazomib citrate with lenalidomide and dexamethasone, post prior therapy for relapsed, refractory multiple myeloma (CDF review of TA505) (ID1635)
  • Dostarlimab for recurrent, advanced, high microsatellite instability, mismatch repair deficiency, treated endometrial cancer (ID3802)
  • Diroximel fumarate for treating relapsing‐remitting multiple sclerosis (ID1673)
  • Ataluren for duchenne muscular dystrophy (nonsense mutation) (review of HST3) [ID1642]